Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Akeso, Inc. (HK:9926)
HKEX:9926
Akeso, Inc. (9926) Stock Price & Analysis
2 Followers
9926 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$26.45 - HK$60.00
Previous CloseHK$40.65
Volume4.67M
Average Volume (3M)9.59M
Market Cap
HK$35.20B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)14.7
Beta1.38
Next Earnings
Aug 20, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.77
Shares Outstanding865,857,176
10 Day Avg. Volume1,466,300
30 Day Avg. Volume9,592,541
Standard Deviation0.20
R-Squared0.14
Alpha-0.00875
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$57.59Price Target Upside41.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Akeso, Inc. News
PremiumCompany Announcements
Akeso, Inc. Schedules Annual General Meeting
PremiumCompany Announcements
Akeso, Inc. Proposes Share Scheme Overhaul
PremiumCompany Announcements
Akeso Broadens Ivonescimab Agreement With SummitPremiumCompany Announcements
Akeso’s Ivonescimab Outperforms in Clinical TrialBulls Say, Bears Say
Bulls Say
Clinical Trial SuccessAkeso's PD-1/VEGF BsAb ivonescimab (AK112) has shown superiority over Keytruda in a head-to-head comparison during a Phase III trial, promising an enhanced treatment for non-small cell lung cancer.
Drug Approval And Market PotentialThe anticipated inclusion of Akeso's cadonilimab in the National Reimbursement Drug List could significantly boost market penetration and sales from early 2026.
Financial PerformanceAkeso has demonstrated strong profitability with a high product gross profit margin of 91.8% and a net profit that underscores the company's financial stability.
Bears Say
Clinical Trial ResultsA published ASCO abstract has seen lower efficacy in Ph III vs previously reported Ph II data for Akeso's AK112.
Market CompetitionAkeso's drug AK112 faces increasing competition from Innovent's already approved and marketed sintilimab.
Market CompetitionEmerging TROP2 ADCs like Kelun Bio/Merck's SKB264 show potential in the NSCLC therapeutic space, posing further competition to Akeso's AK112.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
2.84% Mutual Funds
4.19% Other Institutional Investors
92.97% Public Companies and
Individual Investors
9926 FAQ
What was Akeso, Inc.’s price range in the past 12 months?
Akeso, Inc. lowest stock price was HK$26.45 and its highest was HK$60.00 in the past 12 months.
What is Akeso, Inc.’s market cap?
Currently, no data Available
When is Akeso, Inc.’s upcoming earnings report date?
Akeso, Inc.’s upcoming earnings report date is Aug 20, 2024 which is in 71 days.
How were Akeso, Inc.’s earnings last quarter?
Akeso, Inc. released its earnings results on Mar 18, 2024. The company reported -HK$0.64 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.64.
Is Akeso, Inc. overvalued?
According to Wall Street analysts Akeso, Inc.’s price is currently Undervalued.
Does Akeso, Inc. pay dividends?
Akeso, Inc. does not currently pay dividends.
What is Akeso, Inc.’s EPS estimate?
Akeso, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Akeso, Inc. have?
Akeso, Inc. has 865,857,200 shares outstanding.
What happened to Akeso, Inc.’s price movement after its last earnings report?
Akeso, Inc. reported an EPS of -HK$0.64 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.192%.
Which hedge fund is a major shareholder of Akeso, Inc.?
Currently, no hedge funds are holding shares in HK:9926
---
Akeso, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
16.81%
12-Months-Change
Fundamentals
Return on Equity
57.08%
Trailing 12-Months
Asset Growth
63.82%
Trailing 12-Months
Company Description
Akeso, Inc.
Akeso Inc is a clinical-stage biopharmaceutical company committed to in-house discovery, development, and commercialization of therapies. It is dedicated to addressing global unmet medical needs in oncology, immunology, and other therapeutic areas. The company's drug candidates include AK104 for recurrent or metastatic cervical cancer, Penpulimab (AK105) for the treatment of patients with classical Hodgkin's lymphoma, AK112 for advanced solid tumors, AK101 for the treatment of ulcerative colitis, AK111 for moderate-to-severe psoriasis, Ebronucimab (AK102) for the treatment of patients with a high or very high risk of hypercholesterolemia, and others.
---
9926 Stock 12 Month Forecast
Average Price Target
HK$57.59
▲(41.67% Upside)
Technical Analysis
Best Analysts Covering 9926
1 Year
1 Year Success Rate
1/2 ratings generated profit
1 Year Average Return
+10.70%
reiterated a buy rating 4 months ago
Copying Jialin Zhang's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +10.70% per trade.
---